SCARNA13: A Potential Drug Target and Biomarker for Small Cajal Body-Specific RNA 13

Target Name: SCARNA13

NCBI ID: G677768

SCARNA13

Other Name(s): small Cajal body-specific RNA 13 | Small Cajal body-specific RNA 13 | U93

SCARNA13: A Potential Drug Target and Biomarker for Small Cajal Body-Specific RNA 13

Small Cajal body-specific RNA 13 (SCARNA13) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. SCARNA13 is a small RNA molecule that is expressed in different tissues and cells of the body, including the brain, heart, and kidneys. It is characterized by its unique 13-base pair length and the presence of a specific stem-loop structure in the 5' end.

The discovery of SCARNA13 as a potential drug target and biomarker has significant implications for the development of new treatments for a variety of diseases. The small size of SCARNA13 makes it an attractive target for small molecule inhibitors, which can easily be administered to the target cells without causing significant systemic side effects. Additionally, the fact that SCARNA13 is expressed in various tissues and cells of the body makes it a promising biomarker for disease diagnosis and monitoring.

SCARNA13 has been shown to play a role in several diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. For example, studies have shown that SCARNA13 is overexpressed in neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, and that inhibition of SCARNA13 has been shown to protect against neurodegeneration in these disorders. Additionally, SCARNA13 has also been shown to be overexpressed in cancer cells and that inhibition of SCARNA13 has been shown to enhance the effectiveness of cancer treatments.

In addition to its potential as a drug target, SCARNA13 has also been shown to be a potential biomarker for several diseases. The small size of SCARNA13 makes it an attractive target for diagnostic assays, such as qRT-PCR and western blotting. Studies have shown that SCARNA13 can be effectively detected and quantified in various tissues and cells, making it a promising biomarker for disease diagnosis and monitoring. Additionally, the fact that SCARNA13 is expressed in various tissues and cells of the body makes it a potential source of biomarkers for disease tracking and diagnosis over time.

In conclusion, SCARNA13 is a small RNA molecule that has significant potential as a drug target and biomarker for a variety of diseases. Its unique small size and the presence of a specific stem-loop structure make it an attractive target for small molecule inhibitors, while its expression in various tissues and cells of the body makes it a promising biomarker for disease diagnosis and monitoring. Further research is needed to fully understand the role of SCARNA13 as a drug target and biomarker for various diseases.

Protein Name: Small Cajal Body-specific RNA 13

The "SCARNA13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCARNA13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets